ML-347

Activation of bone morphogenetic protein (BMP) type I receptors, also known as activin receptor-like kinases (ALK1-7), leads to the assembly of SMAD complexes, which translocate to the nucleus to induce transcriptional activation important for normal development and tissue repair. ML-347 is a 5-quinoline compound that inhibits ALK1 and ALK2 with IC50 values of 46 and 32 nM, respectively. It demonstrates >300-fold selectivity for ALK2 over ALK3, ALK6, and VEGF type 2 receptor (IC50s = 10.8, 9.8, and 19.7 µM, respectively) and is inactive at ALK4, ALK5, BMP type 2 receptors, TGF-beta type 2 receptor, and AMPK. In a functional assay, ML-347 was shown to inhibit BMP4 signaling with an IC50 value of 152 nM.Formal Name: 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline. CAS Number: 1062368-49-3. Synonyms: LDN193719. Molecular Formula: C22H16N4O. Formula Weight: 352.4. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 5 mg/ml, DMSO: 10 mg/ml, DMSO:PBS(pH 7.2) (1:2): 0.25 mg/ml. lambdamax: 244, 283 nm. SMILES: COC1=CC=C(C(C=N2)=CN3C2=C(C4=CC=CC5=C4C=CC=N5)C=N3)C=C1. InChi Code: InChI=1S/C22H16N4O/c1-27-17-9-7-15(8-10-17)16-12-24-22-20(13-25-26(22)14-16)18-4-2-6-21-19(18)5-3-11-23-21/h2-14H,1H3. InChi Key: FVRYPYDPKSZGNS-UHFFFAOYSA-N.